...

首页> 外文期刊>Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen >After neoadjuvant therapy of pancreatic cancer the classical radiological criteria for resectability are no longer applicable

【24h】

After neoadjuvant therapy of pancreatic cancer the classical radiological criteria for resectability are no longer applicable

机译：胰腺癌新辅助治疗后，可切除性的经典放射学标准不再适用

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen》 |2015年第2期|共1页
作者
Strobel O.; Buechler M. W.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类外科学;
关键词

相似文献

外文文献
中文文献
专利

1. After neoadjuvant therapy of pancreatic cancer the classical radiological criteria for resectability are no longer applicable [J] . Strobel O., Buechler M. W. Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen . 2015,第2期

机译：胰腺癌新辅助治疗后，可切除性的经典放射学标准不再适用
2. Surgical and Pathologic Outcomes in Patients on a Phase II Trial of Neoadjuvant Chemotherapy and Hypofractionated Image-Guided Intensity Modulated Radiation Therapy (HIGRT) in Resectable and Borderline Resectable Pancreatic Cancer [J] . Stephens S. J., Czito B., Zhang X., International Journal of Radiation Oncology, Biology, Physics . 2018,第3Suppla期

机译：患者的外科和病理结果对Neoadjuvant化疗和低速分配的图像引导强度调制放射治疗（HIGRTT）在可重演和边缘可重型胰腺癌中的患者
3. Favorable perioperative outcomes after resection of borderline resectable pancreatic cancer treated with neoadjuvant stereotactic radiation and chemotherapy compared with upfront pancreatectomy for resectable cancer [J] . Eric A. Mellon, Tobin J. Strom, Sarah E. Hoffe, Journal of Gastrointestinal Oncology . 2016,第4期

机译：与可手术切除的前期胰腺切除术相比，新辅助立体定向放射和化学疗法治疗的交界性可切除胰腺癌的手术围手术期结局良好
4. SEER Based Pancreatic Cancer Resectability Prediction Tool [C] . Lena Abu-El-Haija, Julie Ivy, Walter Park Institute of Industrial and Systems Engineers Annual Conference and Expo . 2021

机译：基于SER的胰腺癌可重视预测工具
5. Does pancreaticoduodenectomy with venous resection increase median survival when compared to palliative therapy in patients with borderline resectable pancreatic adenocarcinoma of the head of the pancreas? [D] . Lennon, Erin Frances 2010

机译：与颅底可重型胰腺腺癌患者的痛苦治疗相比，胰腺切除术治疗中位生存率是否增加了胰腺的头部胰腺炎的患者？
6. Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): study protocol for a nationwide multicenter randomized controlled trial [O] . Q. P. Janssen, J. L. van Dam, B. A. Bonsing, 2021

机译：Neoadjuvant Folfirinox总基于Neoadjuvant Gemcitabine的化学疗法和佐剂吉西他滨用于可重症和边界可重置胰腺癌（Preopanc-2试验）：用于全国多中心随机对照试验的研究方案
7. The Role of Radiological Parameters in Assessing Response to Neoadjuvant Therapy in Borderline Resectable Pancreatic Cancer [O] . Nervana Hussien, Kareem Sallam, Mostafa Abdel-Kawi, 2020

机译：放射性参数在评估对边界可重置胰腺癌中新辅助治疗的反应的作用

获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

客服微信
服务号